Advertisement

Topics

Latest Bioinformatics NewsRSS

14:54 EDT 23rd June 2017 | BioPortfolio

Despite what you’ve heard, human genome is not completely sequenced

Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients

Preclinical Data Demonstrate Synergistic Activity of SY-1425 with Standard-of-Care AML and MDS Therapies and Anti-CD38 Therapies, Strengthening Rationale for Ongoing and Future Clinical Investigation of SY-1425 as Both a Monotherapy and Combination Agent Preclinical Data Elucidates Mechanism of Action of SY-1425 Syros Pharmaceuticals (NASDAQ: ...

Early Data for bluebird bio Gene-Therapy Candidate Show Some Promise

bluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate—including a Phase III study that followed a change in its manufacturing process. In the Phase III Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes, ...

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

Bluebird Bio's trial of a gene therapy for two inherited blood disorders yielded some impressive results Friday ― but also raised key questions.

Early Data for bluebird bio Gene-Therapy Candidate Shows Some Promise

bluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate—including a Phase III study that followed a change in its manufacturing process. In the Phase III Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes, ...

Early Data for bluebird bio Gene Therapy Candidate Shows Some Promise

Bluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate following a change in its manufacturing process. In the Phase III Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes, early interim data showed that the...

BayCare HomeCare Named to 2012 HomeCare Elite

In-depth analysis places BayCare in top 25 percent of Home Care Programs in the U.S. LARGO, Fla., Dec. 27, 2012 /PRNewswire-USNewswire/ -- BayCare HomeCare was once again named as one of the top home care agencies in the nation based on performance measures in quality outcomes, process of care measures and financial performance. (Logo: http://photos.prnewswire.com/prnh/20121227/DC3...

Whole-Genome Study Shows IGF1R Inhibitors May Help Some Osteosarcoma Patients

Researchers report in Nature Communications (“ Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma ”) that a genetic sequencing study has revealed that some patients with osteosarcoma could be helped by an existing drug. The team, from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal Nationa...

Whole Genome Study Shows IGF1R Inhibitors May Help Some Osteosarcoma Patients

Researchers report in Nature Communications (“Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma”) that a genetic sequencing study has revealed that some patients with osteosarcoma could be helped by an existing drug. The team, from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National ...

Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center

SAN DIEGO, Dec. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML). Trovagene holds an exclusive worldwide l...

bluebird bio Touts Impressive Data From Late-Stage Gene Therapy Study

  Life Sciences Jobs   ...

Robert J. Hennessey Appointed Chairman of the Board of Nanotherapeutics

Nanotherapeutics, Inc., a biologics focused contract development and manufacturing organization (CDMO), today announced that Robert J. Hennessey has been appointed Chairman of the Board. Commenting on today’s announcement, Peter H. Khoury, Ph.D., President and Chief Executive Officer of Nanotherapeutics, stated, “We are pleased to welcome Bob ...

Ribosomal DNA Copy Numbers Decrease in Some Cancers

An analysis of human cancer genome projects uncovers a counterintuitive loss of ribosomal gene copies.

Sequenom CMM's MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced today that the MaterniT21™ PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain...

Blood disease that plagued Europe’s royal families might be treatable using gene editing

Shaking Up Genome Regulation by Considering Oil/Water-Like Interactions

In the mixed-up world of gene silencing, it’s not exactly clear why some genomic regions are hard to access. These regions, it has been suggested, may simply be too tightly packed to permit the passage of regulatory proteins needed for gene expression. Tightly packed DNA, however, doesn’t always behave as expected. For example, heterochromatin has been known to exclude small proteins while adm...

Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research

Sweden aims to establish a new Centre for Advanced Medical Products (CAMP) as part of a SEK 320 million ($36.6 million), 8-year Swedish governmental initiative to position the country as a leading biologics developer. Swedish regenerative medicine firm Xintela, has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research centre, with SEK 48 million ($...

Canopy Biosciences Announces Distribution Agreement with Cosmo Bio for Japan Life Science Market

ST. LOUIS, June 22, 2017 /PRNewswire/ -- Canopy BiosciencesTM, LLC ("Canopy Biosciences"), an emerging provider of gene editing and personalized medicine technologies, announced a distributor agreement with Cosmo Bio Co., Ltd. ("Cosmo Bio") for its TUNR Flexible Gene Editing technology in Japan.  Cosmo Bio is one of Japan's largest and most established reagents and services suppliers in ...

Sweden Launches Initiative to Establish Centre for Cell and Gene Therapy Research

Sweden aims to establish a new Centre for Advanced Medical Products (CAMP) as part of a SEK 320 million ($36.6 million), 8-year Swedish governmental initiative to position the country as a leading biologics developer. Swedish regenerative medicine firm Xintela, has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research centre, with SEK 48 million ($...

Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017

CARLSBAD, Calif., June 22, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the completion of enrollment in the Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in patients with Huntington's disease (HD). Dosing in the final patient cohort continues, and Ionis plans to report top-line results from this study around year-end 2017. T...

Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits

CARLSBAD, Calif., Feb. 11, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore® HLA typing kits. The development represents additional execution against the company's strategy to become a leader in the diagnostics market by offering both ...

Brazil's Transgenic Sugarcane Stirs Up Controversy

The recent approval by Brazil of a genetically modified (GM) sugarcane has pleased some scientists and dismayed others, who claim it may threaten biodiversity in the country. The GM sugarcane is designed to help farmers with the sugarcane borer, one of the main pests in sugarcane fields of South-Central Brazil, leading to losses of about US$1.5 billion per year. “Breeding programmes could not pr...

Pacific Biosciences Technology Resolves Complex Maize Genome, Driving Demand For Other Large-Scale AgBio Sequencing Projects

  Life Sciences Jobs   ...

Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business

BALTIMORE, March 7, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, today announced a number of developments that will support its expanding business.  The company licensed exclusive rights to Digital Karyotyping (DK), an important genome-mapping technology developed by the...

Beijing 4P Health Research Institute initiates China’s “100K Wellness Pioneer Project” using UniteGen and Sapientia™ integrated platform

Commercial agreement with Congenica supports UniteGen’s goal of achieving the world's largest human genome database Cambridge, UK - 21 June 2017 - Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer ...

Quick Search
Advertisement
 

review and buy Bioinformatics market research data and corporate reports here